Payment overview · 2025
General Payments
$425.94
20 reported records · 10 companies
Healthcare provider profile · identity verified
Eric J. Milie, DO
Allopathic & Osteopathic Physicians|Internal Medicine · ERIE, PA · NPI 1396795100
Verified facts
What the public records show
CMS Open Payments records show Eric J. Milie, DO received $425.94 in general payments during 2025 across 20 reported records.
Alkermes, Inc. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Vivitrol.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vivitrol by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $90.46 | 21.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.52 | 20.1% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $58.75 | 13.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.91 | 9.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $35.25 | 8.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.35 | 7.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.21 | 6.9% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $22.36 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.19 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.94 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $425.94 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $90.46 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.31 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $58.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.09 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $35.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VIVITROL vivitrol |
2025 | Vivitrol | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 195 | 46 |
| Gabapentin | Gabapentin | 154 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 45 |
| Methylprednisolone | Methylprednisolone | 125 | 114 |
| Lisinopril | Lisinopril | 122 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 36 |
| Losartan Potassium | Losartan Potassium | 89 | 18 |
| Omeprazole | Omeprazole | 79 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 20 |
| Meloxicam | Meloxicam | 73 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | suppressed |
| Nabumetone | Nabumetone | 65 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 17 |
| Allopurinol | Allopurinol | 57 | 12 |
| Lorazepam | Lorazepam | 57 | 11 |
| Furosemide | Furosemide | 55 | 25 |
| Metformin Hcl | Metformin Hcl | 53 | 17 |
| Trazodone Hcl | Trazodone Hcl | 53 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 18 |
| Azithromycin | Azithromycin | 49 | 41 |
| Eliquis | Apixaban | 49 | 14 |
| Simvastatin | Simvastatin | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 42 | 42 |
| Famotidine | Famotidine | 39 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 21 |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Cephalexin | Cephalexin | 26 | 21 |
| Lactated Ringers | Ringer's Solution,lactated | 26 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 11 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pacerone | Amiodarone Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vivitrol | Naltrexone Microspheres | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $425.94 · 20 records | Alkermes, Inc. | CAPLYTA, INSPIRE, JARDIANCE, LUMRYZ, Leqembi, MOUNJARO, OFEV, Ozempic, Prolastin-C Liquid, The Cologuard Plus Collection Kit, VIVITROL, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error